About Forus
Leadership
Values
Latest News
FORUS Therapeutics Inc (“FORUS”) Announces XPOVIO® (selinexor) Is Authorized for Sale by Health Canada
(OAKVILLE, Ontario) June 7, 2022 – FORUS Therapeutics Inc ("FORUS"), is pleased to announce that on May 31, 2022 XPOVIO® (selinexor) was authorized for sale by Health Canada in combination with bortezomib and dexamethasone for the treatment of adult patients with...
FORUS was a proud sponsor and participant in the Défi Cyclo-Myélome on May 28th, 2022
(Saint-lgnace-de-Stanbridge, Quebec) May 28th, 2022 – FORUS was a proud sponsor and participant in the Défi Cyclo-Myélome. This is the 10th year of this important event which aims to increase awareness about multiple myeloma and raise funds for the Myeloma Canada...
FORUS Therapeutics will be presenting at the Bloom Burton & Co. Healthcare Investor Conference on May 3rd, 2022
(TORONTO, Ontario) May 2-3, 2022 – FORUS Therapeutics Inc, a Canadian Life Sciences company specialized in developing and commercializing unique and differentiated oncology focused therapies is proud to be participating and presenting at the 2022 Bloom Burton &...
Contact Us
Mailing Address:
FORUS Therapeutics Inc.
200 North Service Road West, Suite 129
Oakville, Ontario, L6M 2Y1
Phone: 1-877-359-9595
Fax: 1-877-359-9590
Patient Support:
Phone: 1-833-4YOUPSP (1-833-496-8777)
Fax: 1-833-4YOUFAX (1-833-496-8329)
Product Support:
Phone: 1-866-542-7500
Fax: 1-866-542-1100
Do not use this form to report adverse events. Adverse events can be reported at 1-866-542-7500.